NCT05340309

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Active, enrolled Phase 2 Last updated 29 January 2026

What this trial tests

Phase 2 trial testing Atezolizumab and Recombinant Human Hyaluronidase in Lung Non-Small Cell Carcinoma in 5 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 December 2022

Primary endpoint
31 December 2026

31 December 2027

Quick facts

Lead sponsor	University of Southern California
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	7 December 2022
Primary completion	31 December 2026
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

• Atezolizumab and Recombinant Human Hyaluronidase — full drug profile →
• Survey Administration

Conditions studied

• Lung Non-Small Cell Carcinoma — all drugs for Lung Non-Small Cell Carcinoma →
• Stage II Lung Cancer AJCC v8 — all drugs for Stage II Lung Cancer AJCC v8 →
• Stage IIA Lung Cancer AJCC v8 — all drugs for Stage IIA Lung Cancer AJCC v8 →
• Stage IIB Lung Cancer AJCC v8 — all drugs for Stage IIB Lung Cancer AJCC v8 →

Sponsor

University of Southern California

Who can join

18 and older, any sex, with Lung Non-Small Cell Carcinoma or Stage II Lung Cancer AJCC v8. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study may help determine if a telemedicine based approach that gives atezolizumab at home using a version of the drug designed for subcutaneous injection under the skin is safe and feasible.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

1. Hyaluronidase: structure, mechanism of action, diseases and therapeutic targets.
   Lu J, Zhao Z, Pan L, Wu H, et al · · 2025 · cited 19× · PMID 40646377 · DOI 10.1186/s43556-025-00299-y
2. Stick With Intravenous or Give Subcutaneous a Shot? Time and Other Considerations When Evaluating Cancer Drug Formulations.
   Gupta A, Tregear M, Pace MB, Vogel RI. · · 2025 · cited 4× · PMID 39094070 · DOI 10.1200/op-24-00501
3. Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer.
   Grobler L, O'Connor D, Rischin D, Putrik P, et al · · 2025 · cited 2× · PMID 40260850 · DOI 10.1002/14651858.cd014861.pub2
4. Decentralized Clinical Trials in Early Drug Development-A Framework Proposal.
   Silva DJ, Nelson BE, Rodon J. · · 2024 · cited 2× · PMID 39219999 · DOI 10.36401/jipo-23-33
5. Decentralized Clinical Trials in the Era of Real-World Evidence: A Critical Assessment of Recent Experiences.
   Wang H, Daizadeh N, Shen YL, Chen J, et al · · 2025 · PMID 40920390 · DOI 10.1111/cts.70328